ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0475

Prevalence of Endometriosis and Polycystic Ovarian Syndrome in Patients with Rheumatic Diseases in the United States

Sabahat Usmani1, Catherine Lavallee2, Maria Antonelli3 and Cuoghi Edens4, 1Weiss Memorial Hospital, Chicago, IL, 2Virginia Tech Carilion School of Medicine, Roanoke, VA, 3MetroHealth System, Cleveland, OH, 4University of Chicago, Chicago, IL

Meeting: ACR Convergence 2023

Keywords: population studies, pregnancy, rheumatoid arthritis, Systemic lupus erythematosus (SLE), Women's health

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0460–0479) Reproductive Issues in Rheumatic Disorders Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Endometriosis (ENDO) and Polycystic Ovarian Syndrome (PCOS) are underdiagnosed, often debilitating conditions with unknown etiologies that, like rheumatic diseases, affect reproductive-aged women. Recent studies suggest an association between ENDO across autoimmune diseases; PCOS has not been examined. The purpose of our study is to determine the prevalence and association of these conditions in patients with rheumatologic diseases in a large ambulatory population.

Methods: Utilizing the secure cloud-based platform, IBM® Explorys®, we conducted a retrospective cross-sectional study of females, ages 10-49, from the United States with PCOS or ENDO and rheumatic diseases using pooled deidentified data from multiple US health-care systems using Epic® electronic medical record platform, collected from 1999 to 2022. Rheumatic diseases examined: Juvenile idiopathic arthritis (JIA) Psoriatic arthritis (PsA) Axial spondyloarthritis (AS) Rheumatoid arthritis (RA) Systemic lupus erythematosus (SLE) Mixed or undifferentiated connective tissue disease (CTD) Inflammatory Myositis (IM) Sjogren’s disease (SD) Systemic Sclerosis (SSc).Females in the IBM® Explorys® platform with no rheumatic diseases served as the control group representing the general population. Chi-squared test and odds ratio (OR) were calculated.

Results: RA was present in 1% of the Explorys® population, in line with established epidemiologic data, serving as validation of the data set. The prevalence of PCOS and ENDO in the general population was under 2%, regardless of age.900,600 women had one of the queried rheumatic diseases, with 194,200 ages 10-49. In those with a rheumatic disease, 3% and 3.9% had PCOS and ENDO, in those 10-49 prevalence was 3.9% and 5.8%, respectively. Table 1 contains prevalence for each specific rheumatic disease. SD had the highest ENDO prevalence and SD, JIA, AS, and CTD the highest prevalence of PCOS. There is evidence that there is an association between each unique rheumatic disease or as a whole with ENDO (p< 0.0001) and PCOS (p< 0.0001).

If age 10-49 with a rheumatic disease, the odds of having PCOS was 4.3 (4.24-4.38) times higher than in the general population with the odds of having ENDO 13.34 (13.15-13.54).In this demographic, SD, AS and CTD had the highest likelihood of both ENDO and PCOS, which can be found in Table 2.Across all ages, JIA and CTD had the highest likelihood of PCOS and ENDO. SLE also had one of the highest likelihoods of having ENDO across all ages.

Conclusion: Increased prevalence and evidence of association exist between rheumatic diseases and both PCOS and ENDO compared to the general population when examined in a large electronic medical record platform. Additionally, there is an increased likelihood of having PCOS or ENDO in all rheumatic diseases analyzed. Future studies are needed to identify the mechanisms contributing to these findings of PCOS and ENDO in patients with rheumatic diseases as well as increased awareness of these underdiagnosed conditions amongst those who care for these patients to aid in their diagnosis and care.

Supporting image 1

Supporting image 2


Disclosures: S. Usmani: None; C. Lavallee: None; M. Antonelli: None; C. Edens: None.

To cite this abstract in AMA style:

Usmani S, Lavallee C, Antonelli M, Edens C. Prevalence of Endometriosis and Polycystic Ovarian Syndrome in Patients with Rheumatic Diseases in the United States [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/prevalence-of-endometriosis-and-polycystic-ovarian-syndrome-in-patients-with-rheumatic-diseases-in-the-united-states/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-endometriosis-and-polycystic-ovarian-syndrome-in-patients-with-rheumatic-diseases-in-the-united-states/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology